Publications
Explore the latest GNPC-related publications
View five GNPC publications in Nature Medicine, including the GNPC's Summary Paper, three deep-dive scientific papers, and a World View perspective from Bill Gates
1. The Global Neurodegeneration Proteomics Consortium: Biomarker and Drug Target Discovery for common neurodegenerative diseases and aging (Imam, et al)
2. Plasma proteomic landscape of Alzheimer’s, Parkinson’s, and Frontotemporal dementia uncovers shared and disease-specific pathways (Ali, et al)
3. Aging and dementia disrupt CSF-plasma protein balance (Farinas, et al)
4. Systemic immune-related proteome changes are shared by APOE4 carriers across neurodegenerative diseases (Shvetcov, et al)
5. Global collaboration is key to decoding Alzheimer’s disease (Gates)
A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer’s disease
Findings underscore CSF YWHAG:NPTX2 as a robust prognostic biomarker for cognitive resilience versus AD onset and progression, highlight the potential of plasma proteomics in replacing CSF measurement and further implicate synapse dysfunction as a core driver of AD dementia.
Disruption of the cerebrospinal fluid–plasma protein balance in cognitive impairment and aging
This work provides molecular insight into the human brain barrier system and its disruption with age and disease, with implications for the development of brain-permeable therapeutics.
Benchmarking the AI-based diagnostic potential of plasma proteomics for neurodegenerative disease in 17,170 people
This paper presents ProtAIDe-Dx, a deep joint-learning model trained on 17,170 patients and controls that uses plasma proteomics to provide simultaneous probabilistic diagnosis across six conditions associated with dementia in aging.
GNPC: Mining 40,000 Fluid Samples for Neurodegeneration Markers
AlzForum reports that the Global Neurodegeneration Proteomics Consortium (GNPC) has created the largest-ever proteomics dataset for neurodegenerative diseases, analyzing over 40,000 fluid samples across conditions like Alzheimer’s, Parkinson’s, and ALS. This public–private initiative aims to uncover protein biomarkers to aid in early diagnosis, track disease progression, and guide treatment development.
Large-scale plasma proteomics uncovers preclinical molecular signatures of Parkinson’s disease and overlap with other neurodegenerative disorders
This extensive proteomics effort identified novel, actionable biomarkers opening new avenues for early PD risk stratification and precision medicine.
Contact Us
Please contact info@neuroproteome.org with inquiries about joining the Global Neurodegeneration Proteomics Consortium (GNPC) or questions about accessing the resulting data.
